Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Public ClinicalTrials.gov record NCT03976375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)
Study identification
- NCT ID
- NCT03976375
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 422 participants
Conditions and interventions
Conditions
Interventions
- Docetaxel Drug
- Lenvatinib Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2019
- Primary completion
- Aug 10, 2023
- Completion
- Aug 21, 2024
- Last update posted
- Aug 14, 2025
2019 – 2024
United States locations
- U.S. sites
- 28
- U.S. states
- 14
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604) | Bakersfield | California | 93309 | — |
| Cancer Specialists of North Florida - Fleming Island ( Site 1675) | Fleming Island | Florida | 32003 | — |
| Mid-Florida Cancer Centers ( Site 1611) | Orange City | Florida | 32763 | — |
| University of Kentucky School of Medicine & Hospitals ( Site 1621) | Lexington | Kentucky | 40536 | — |
| Hematology Oncology Clinic ( Site 1680) | Baton Rouge | Louisiana | 70809 | — |
| Harry & Jeanette Weinberg Cancer Institute ( Site 1626) | Baltimore | Maryland | 21237 | — |
| Medstar Good Samaritan Hospital ( Site 1625) | Baltimore | Maryland | 21239 | — |
| Massachusetts General Hospital ( Site 1622) | Boston | Massachusetts | 02114 | — |
| MGH - North Shore Cancer Center ( Site 1668) | Danvers | Massachusetts | 01923 | — |
| The Mass General Cancer Center at Newton-Wellesley ( Site 1692) | Newton | Massachusetts | 02462 | — |
| University of Massachusetts Medical School ( Site 1693) | Worcester | Massachusetts | 01655 | — |
| Billings Clinic ( Site 1631) | Billings | Montana | 59101 | — |
| Bozeman Health Deaconness Cancer Center ( Site 1632) | Bozeman | Montana | 59715 | — |
| Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 1664) | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan-Kettering Cancer Center at Middletown ( Site 1665) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan-Kettering Cancer Center at Montvale ( Site 1667) | Montvale | New Jersey | 07645 | — |
| Memorial Sloan-Kettering Cancer Center at Commack ( Site 1662) | Commack | New York | 11725 | — |
| Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 1666) | Harrison | New York | 10604 | — |
| Memorial Sloan-Kettering Cancer Center ( Site 1661) | New York | New York | 10065 | — |
| New York Cancer and Blood Specialists ( Site 1696) | Port Jefferson Station | New York | 11776 | — |
| University of Rochester ( Site 1638) | Rochester | New York | 14642 | — |
| Memorial Sloan Kettering Cancer Center - Nassau ( Site 1670) | Uniondale | New York | 11553 | — |
| TriHealth Cancer Institute ( Site 1672) | Cincinnati | Ohio | 45220 | — |
| MetroHealth Medical Center ( Site 1694) | Cleveland | Ohio | 44109 | — |
| Kaiser Permanente Center for Health Research-Kaiser Permanente Medical Center ( Site 1644) | Portland | Oregon | 97227 | — |
| Fox Chase Cancer Center ( Site 1647) | Philadelphia | Pennsylvania | 19111 | — |
| Thompson Cancer Survival Center ( Site 1695) | Knoxville | Tennessee | 37916 | — |
| Millenium Physicians ( Site 1690) | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03976375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03976375 live on ClinicalTrials.gov.